Xencor, Inc.
XNCR
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndromeā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$20.21
Price-5.96%
-$1.28
1Y
Price
Market Cap
$1.498b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+20.1%
EBITDA Margin-28.7%
Net Profit Margin-147.6%
Free Cash Flow Margin+20.1%
EBITDA Margin-28.7%
Net Profit Margin-147.6%
Free Cash Flow MarginRevenue
$97.360m
+51.5%
1y CAGR+7.0%
3y CAGR-4.8%
5y CAGREarnings
-$172.421m
+40.4%
1y CAGR-58.5%
3y CAGR-85.6%
5y CAGREPS
-$2.29
+47.5%
1y CAGR-49.4%
3y CAGR-79.0%
5y CAGRBook Value
$515.633m
$736.846m
Assets$221.213m
Liabilities$175.164m
DebtDebt to Assets
23.8%
-2.9x
Debt to EBITDAFree Cash Flow
-$188.841m
+31.0%
1y CAGR-164.8%
3y CAGR-113.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company